Richard Peter Marshall Buys 12,183 Shares of Serina Therapeutics (NYSEAMERICAN:SER) Stock

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Director Richard Peter Marshall bought 12,183 shares of the business’s stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average cost of $1.65 per share, with a total value of $20,101.95. Following the completion of the acquisition, the director owned 12,183 shares in the company, valued at approximately $20,101.95. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Serina Therapeutics Price Performance

NYSEAMERICAN:SER opened at $1.98 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 4.18 and a current ratio of 4.18. The stock has a market cap of $29.70 million, a price-to-earnings ratio of -0.99 and a beta of 1.15. The company’s 50 day moving average price is $1.95. Serina Therapeutics, Inc. has a 1-year low of $1.22 and a 1-year high of $7.92.

Serina Therapeutics (NYSEAMERICAN:SER) last posted its earnings results on Thursday, May 14th. The company reported ($0.58) earnings per share for the quarter.

About Serina Therapeutics

Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.